Therapeutic Peptides, Inc. – Trademark Portfolio
Entity Type: 03
Therapeutic Peptides, Inc. holds 19 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 17 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 10 trademarks are registered. Notable registered marks include TPI, CHELASYN, DERMALYSIN, STIMULYSIN, and AMPHITRICIN. The owner is based in Baton Rouge, LA.
11577 Mercantile Drive
Baton Rouge, LA 70809
Showing of trademarks Trademarks
Trademark Classifications
Therapeutic Peptides, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Therapeutic Peptides, Inc. have?
Therapeutic Peptides, Inc. has 19 U.S. trademarks filed with the USPTO. Of these, 10 registered, 2 abandoned, 7 cancelled.
What trademark classes does Therapeutic Peptides, Inc. file in?
Therapeutic Peptides, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 3 (Cosmetics & Cleaning). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Therapeutic Peptides, Inc.'s most well-known trademarks?
Therapeutic Peptides, Inc.'s registered trademark portfolio includes well-known marks such as TPI, CHELASYN, DERMALYSIN, STIMULYSIN, and AMPHITRICIN. These are among 10 currently registered trademarks in the portfolio.
What is Therapeutic Peptides, Inc.'s trademark registration success rate?
Therapeutic Peptides, Inc. has a 53% trademark registration rate, with 10 out of 19 resolved applications resulting in successful registration. Currently, 0 applications are pending review.